The category of ALK -rearranged mesenchymal neoplasms has been evolving rapidly, with reports of morphologically diverse lesions of cutaneous, soft tissue, and visceral origin. While some of these represent morphologically defined entities harboring recurrent ALK fusions (inflammatory myofibroblastic tumor and epithelioid fibrous histiocytoma), others are unclassified by morphology with variable overlap with the tyrosine kinase family of neoplasia and their underlying ALK fusions cannot be suspected based on morphology. We herein report 3 cases that expand the anatomic, morphologic, and genotypic spectrum of ALK -rearranged unclassified neoplasms. Patients were all adults aged 46 to 69 (median: 63) who presented with a mass located in the gingiva, subcutis of the back, and submucosal posterior pharyngeal wall. The tumor size ranged from 1 to 2.7 cm (median: 1.6). Conservative surgery was the treatment in all patients. Follow-up was available for one patient who remained disease-free at 14 months. Histologically, all tumors displayed large polygonal cells with foamy to granular and lipogenic-like microvacuolated copious cytoplasm and medium-sized round nuclei with 1 or 2 prominent nucleoli. Mitoses and necrosis were not seen. The initial diagnostic impression was PEComa, inflammatory rhabdomyoblastic tumor and unclassified pseudolipogenic neoplasm. Strong cytoplasmic ALK was detected by immunohistochemistry in all cases. Other positive markers include Cathepsin K (2/2), desmin (1/3), focal MyoD1 (1/1), focal SMA (1/3), and focal EMA (1/2). Targeted RNA sequencing revealed ALK fusions with exon 20 (2 cases) and exon 19 (one case) of ALK fused to RND3 (exon 3), SQSTM1 (exon 6), and desmin (intron 6). Methylation profiling in the desmin-fused case (initially diagnosed as inflammatory rhabdomyoblastic tumor) revealed an inflammatory myofibroblastic tumor match with a low confidence score of 0.5 and a flat copy number variation (CNV) profile. No NF1 mutation was detected in this case, altogether excluding an inflammatory rhabdomyoblastic tumor. Our study highlights and expands the morphologic and anatomic diversity of ALK- fused neoplasms and documents novel fusion partners ( RND3 and desmin).

Bioptical Laboratory Ltd Plzen Czech Republic

Comprehensive Cancer Center European Metropolitan Area Erlangen Nuremberg Erlangen Germany

Department of Cellular Pathology University Hospitals Birmingham Birmingham UK

Department of Pathology and Immunology Washington University School of Medicine St Louis MO

Department of Pathology and Laboratory Medicine Mount Sinai Hospital and Laboratory Medicine and Pathobiology University of Toronto Canada

Department of Pathology Faculty of Medicine Charles University Plzen Czech Republic

Institute of Pathology Erlangen University Hospital Friedrich Alexander University of Erlangen Nuremberg

See more in PubMed

Lovly CM, Gupta A, Lipson D, et al. Inflammatory myofibroblastic tumors harbor multiple potentially actionable kinase fusions. Cancer Discov. 2014;4:889–895.

Dickson BC, Swanson D, Charames GS, et al. Epithelioid fibrous histiocytoma: molecular characterization of ALK fusion partners in 23 cases. Mod Pathol. 2018;31:753–762.

Kazakov DV, Kyrpychova L, Martinek P, et al. ALK Gene fusions in epithelioid fibrous histiocytoma: a study of 14 cases, with new histopathological findings. Am J Dermatopathol. 2018;40:805–814.

Georgantzoglou N, Green D, Winnick KN, et al. Molecular investigation of ALK-rearranged epithelioid fibrous histiocytomas identifies CLTC as a novel fusion partner and evidence of fusion-independent transcription activation. Genes Chromosomes Cancer. 2022;61:471–480.

Cohen JN, Yeh I, Jordan RC, et al. Cutaneous non-neural granular cell tumors harbor recurrent ALK gene fusions. Am J Surg Pathol. 2018;42:1133–1142.

Perret RE, Jullie ML, Vergier B, et al. A subset of so-called dermal non-neural granular cell tumours are underlined by ALK fusions, further supporting the idea that they represent a vari ant of epithelioid fibrous histiocytoma. Histopathology. 2018;73:532–534.

Dermawan JK, Azzato EM, Goldblum JR, et al. Superficial ALK-rearranged myxoid spindle cell neoplasm: a cutaneous soft tissue tumor with distinctive morphology and immunophenotypic profile. Mod Pathol. 2021;34:1710–1718.

Gestrich CK, Davis JL, Biederman L, et al. ALK-rearranged epithelioid mesenchymal neoplasm: expanding the spectrum of tyrosine kinase-altered mesenchymal tumors. Mod Pathol. 2023;36:100334.

Chang KTE, Tay AZE, Kuick CH, et al. ALK-positive histiocytosis: an expanded clinicopathologic spectrum and frequent presence of KIF5B-ALK fusion. Mod Pathol. 2019;32:598–608.

Farinha P, Subtil A, Carr A, et al. + hyaline vascular Castleman disease: a new kid on the block. Histopathology. 2022;80:1007–1010.

Klubíčková N, Michal M, Agaimy A, et al. TIMP3::ALK fusions characterize a distinctive myxoid fibroblastic tumor of the vocal cords: a report of 7 cases. Virchows Arch. 2022;481:721–729.

Robinson JT, Thorvaldsdóttir H, Winckler W, et al. Integrative genomics viewer. Nature Biotechnology. 2011;29:24–26.

Capper D, Jones DTW, Sill M, et al. DNA methylation-based classification of central nervous system tumours. Nature. 2018;555:469–474.

Koelsche C, Schrimpf D, Stichel D, et al. Sarcoma classification by DNA methylation profiling. Nat Commun. 2021;12:498.

Requena L, Hornick JL. Epithelioid fibrous histiocytoma. WHO Classification of Tumours Editorial Board Skin tumours 5th edn. Lyon, France: International Agency for Research on Cancer. (Online version ahead of print).

Kazlouskaya V, Ho J, Jedrych J, et al. Spindle cell variant of epithelioid cell histiocytoma (spindle cell histiocytoma) with ALK gene fusions: cases series and review of the literature. J Cutan Pathol. 2021;48:837–841.

Mansour B, Donati M, Michalová K, et al. Epithelioid fibrous histiocytoma: three diagnostically challenging cases with novel ALK gene fusions, unusual storiform growth pattern, and a prominent spindled morphology. Virchows Arch. 2022;481:751–757.

Antonescu CR. Emerging soft tissue tumors with kinase fusions: an overview of the recent literature with an emphasis on diagnostic criteria. Genes Chromosomes Cancer. 2020;59:437–444.

Klubíčková N, Dermawan JK, Mosaieby E, et al. Comprehensive clinicopathological, molecular, and methylation analysis of mesenchymal tumors with NTRK and other kinase gene aberrations. J Pathol. 2024;263:61–73.

Dermawan JK, DiNapoli SE, Mullaney KA, et al. ALK-rearranged mesenchymal neoplasms: a report of 9 cases further expanding the clinicopathologic spectrum of emerging kinase fusion positive group of tumors. Genes Chromosomes Cancer. 2023;62:75–84.

Coppock JD, Schneider MA, Surrey LF, et al. S100 and CD34 expressing mesenchymal neoplasm with rare PLEKHH2::ALK fusion and response to ALK inhibition. Am J Surg Pathol. 2022;46:1309–1313; d.

Sheng SJ, Li JM, Fan QH, et al. Case report: ALK-rearranged spindle and epithelioid cell neoplasms with S100 and CD34 co-expression: additional evidence of kinase fusion-positive soft tissue tumors. Front Oncol. 2022;12:1007296.

LeBoit PE, Barr RJ, Burall S, et al. Primitive polypoid granular cell tumor and other cutaneous granular-cell neoplasms of apparent nonneural origin. Am J Surg Pathol. 1991;15:48–58.

Lazar AJF, Fletcher CDM. Primitive nonneural granular cell tumors of skin: clinicopathologic analysis of 13 cases. Am J Surg Pathol. 2005;29:927–934.

Chaudhry IH, Calonje E. Dermal non-neural granular cell tumour (so-called primitive polypoid granular cell tumour): a distinctive entity further delineated in a clinicopathological study of 11 cases. Histopathology. 2005;47:179–185.

Xu B, Suurmeijer AJH, Agaram NP, et al. Head and neck mesenchymal tumors with kinase fusions: a report of 15 cases with emphasis on wide anatomic distribution and diverse histologic appearance. Am J Surg Pathol. 2023;47:248–258.

Jie W, Andrade KC, Lin X, et al. Pathophysiological functions of Rnd3/RhoE. Compr Physiol. 2015;6:169–186.

Lamark T, Svenning S, Johansen T. Regulation of selective autophagy: the p62/SQSTM1 paradigm. Essays Biochem. 2017;61:609–624.

Cueto-Ureña C, Mocholí E, Escrivá-Fernández J, et al. Rnd3 expression is necessary to maintain mitochondrial homeostasis but dispensable for autophagy. Front Cell Dev Biol. 2022;10:834561.

Belgiovine C, Frapolli R, Bonezzi K, et al. Reduced expression of the ROCK inhibitor Rnd3 is associated with increased invasiveness and metastatic potential in mesenchymal tumor cells. PLoS One. 2010;5:e14154.

Paysan L, Piquet L, Saltel F, et al. Rnd3 in cancer: a review of the evidence for tumor promoter or suppressor. Mol Cancer Res. 2016;14:1033–1044.

Hnia K, Ramspacher C, Vermot J, et al. Desmin in muscle and associated diseases: beyond the structural function. Cell Tissue Res. 2015;360:591–608.

Herrmann H, Cabet E, Chevalier NR, et al. Dual functional states of R406W-Desmin assembly complexes cause cardiomyopathy with severe intercalated disc derangement in humans and in knock-in mice. Circulation. 2020;142:2155–2171.

Michal M, Rubin BP, Kazakov DV, et al. Inflammatory leiomyosarcoma shows frequent co-expression of smooth and skeletal muscle markers supporting a primitive myogenic phenotype: a report of 9 cases with a proposal for reclassification as low-grade inflammatory myogenic tumor. Virchows Arch. 2020;477:219–230.

Arbajian E, Köster J, Vult von Steyern F, et al. Inflammatory leiomyosarcoma is a distinct tumor characterized by near-haploidization, few somatic mutations, and a primitive myogenic gene expression signature. Mod Pathol. 2018;31:93–100.

Pareja F, Brandes AH, Basili T, et al. Loss-of-function mutations in ATP6AP1 and ATP6AP2 in granular cell tumors. Nat Commun. 2018;9:3533.

Uhrig S, Ellermann J, Walther T, et al. Accurate and efficient detection of gene fusions from RNA sequencing data. Genome Res. 2021;31:448–460.